Marder and colleagues identified that the most common postmarketing adverse events associated with olanzapine IM included pyrexia, hypotension, syncope, neuroleptic malignant syndrome, somnolence, cardiac arrest, rise in the serum creatine phosphokinase (CPK), and falls [18]. This evidence concerns the gene PIK3C2A and Fever.